1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIDA Targeted SBIR and STTR Funding Opportunities is sponsored by National Institute on Drug Abuse (NIDA). NIDA offers targeted SBIR/STTR solicitations focused on specific research areas related to substance use disorders (SUDs). This includes SUD Drug Discovery and Development, and NIDA has a history of funding AI-native startups leveraging machine learning and predictive analytics for addiction science.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses with innovative technologies targeting substance use disorders. (General NIH SBIR/STTR eligibility requirements apply). Confirm the full requirements in the official notice before applying.
The current listing shows normally may not exceed $306,872 for Phase I, and $2,045,816 for Phase II, unless proposal falls under one of the approved topics. Verify award ceilings, matching requirements, and allowable costs in the official notice.
NIDA Targeted SBIR and STTR Funding Opportunities is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article